Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 86 | 2024 | 5716 | 4.940 |
Why?
|
Graft vs Host Disease | 36 | 2024 | 3049 | 2.470 |
Why?
|
Hepatic Veno-Occlusive Disease | 12 | 2020 | 220 | 1.820 |
Why?
|
Thrombotic Microangiopathies | 5 | 2021 | 124 | 1.720 |
Why?
|
Transplantation Conditioning | 22 | 2024 | 1601 | 1.610 |
Why?
|
Polydeoxyribonucleotides | 10 | 2020 | 136 | 1.080 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2024 | 1559 | 1.050 |
Why?
|
Child | 110 | 2024 | 80771 | 0.840 |
Why?
|
Myelodysplastic Syndromes | 6 | 2023 | 1399 | 0.750 |
Why?
|
Bone Marrow Transplantation | 14 | 2023 | 2710 | 0.730 |
Why?
|
Bronchiolitis Obliterans | 3 | 2019 | 221 | 0.700 |
Why?
|
Carboplatin | 4 | 2020 | 790 | 0.690 |
Why?
|
Wilms Tumor | 1 | 2022 | 378 | 0.650 |
Why?
|
Child, Preschool | 70 | 2024 | 42606 | 0.650 |
Why?
|
Cytomegalovirus Infections | 2 | 2016 | 836 | 0.630 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 11872 | 0.630 |
Why?
|
Hematologic Neoplasms | 7 | 2019 | 1907 | 0.610 |
Why?
|
Transplantation, Homologous | 27 | 2024 | 4838 | 0.610 |
Why?
|
Leukemia, Myeloid, Acute | 8 | 2024 | 3626 | 0.550 |
Why?
|
Neuroblastoma | 5 | 2019 | 1266 | 0.550 |
Why?
|
Thalassemia | 2 | 2018 | 267 | 0.530 |
Why?
|
Myeloablative Agonists | 5 | 2019 | 210 | 0.520 |
Why?
|
Adolescent | 80 | 2024 | 89046 | 0.510 |
Why?
|
Transplantation, Autologous | 10 | 2022 | 2118 | 0.510 |
Why?
|
Donor Selection | 1 | 2017 | 242 | 0.490 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2024 | 305 | 0.490 |
Why?
|
Erythrocyte Transfusion | 3 | 2018 | 575 | 0.480 |
Why?
|
Mutagens | 2 | 2005 | 181 | 0.470 |
Why?
|
Ascites | 1 | 2016 | 336 | 0.460 |
Why?
|
Infant | 46 | 2024 | 36485 | 0.450 |
Why?
|
Pleural Effusion | 1 | 2016 | 344 | 0.420 |
Why?
|
Retrospective Studies | 50 | 2024 | 81659 | 0.420 |
Why?
|
Rwanda | 7 | 2022 | 671 | 0.410 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2024 | 686 | 0.400 |
Why?
|
Immunocompromised Host | 2 | 2019 | 862 | 0.400 |
Why?
|
Leukemia | 4 | 2023 | 1518 | 0.390 |
Why?
|
Acute Kidney Injury | 3 | 2021 | 1946 | 0.380 |
Why?
|
Acute Lung Injury | 3 | 2022 | 377 | 0.380 |
Why?
|
Family | 2 | 2021 | 3210 | 0.370 |
Why?
|
Glomerular Filtration Rate | 1 | 2020 | 2227 | 0.370 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 3 | 2019 | 272 | 0.360 |
Why?
|
Catheterization | 1 | 2016 | 1430 | 0.360 |
Why?
|
Immunosuppressive Agents | 7 | 2020 | 4210 | 0.350 |
Why?
|
Drainage | 1 | 2016 | 1183 | 0.350 |
Why?
|
Humans | 147 | 2024 | 767040 | 0.350 |
Why?
|
Lung Diseases | 2 | 2019 | 1942 | 0.340 |
Why?
|
Multiple Organ Failure | 5 | 2020 | 389 | 0.330 |
Why?
|
Bone Marrow | 2 | 2019 | 2926 | 0.330 |
Why?
|
Treatment Outcome | 32 | 2024 | 65295 | 0.320 |
Why?
|
Fibrinolytic Agents | 6 | 2020 | 2079 | 0.320 |
Why?
|
Hodgkin Disease | 3 | 2020 | 1383 | 0.310 |
Why?
|
Neoplasms | 14 | 2024 | 22350 | 0.300 |
Why?
|
Viscera | 1 | 2008 | 138 | 0.300 |
Why?
|
Antineoplastic Agents | 9 | 2022 | 13650 | 0.300 |
Why?
|
Pravastatin | 1 | 2010 | 393 | 0.300 |
Why?
|
Male | 85 | 2024 | 364203 | 0.290 |
Why?
|
Herpesvirus 3, Human | 1 | 2008 | 159 | 0.290 |
Why?
|
Fever | 2 | 2015 | 1605 | 0.290 |
Why?
|
Burkitt Lymphoma | 3 | 2008 | 338 | 0.290 |
Why?
|
Female | 86 | 2024 | 396660 | 0.290 |
Why?
|
Stem Cell Transplantation | 8 | 2018 | 1596 | 0.290 |
Why?
|
Antifungal Agents | 1 | 2012 | 760 | 0.280 |
Why?
|
Etoposide | 3 | 2020 | 639 | 0.280 |
Why?
|
Recurrence | 14 | 2024 | 8504 | 0.280 |
Why?
|
Disease-Free Survival | 11 | 2024 | 6844 | 0.280 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2227 | 0.270 |
Why?
|
Herpes Zoster | 1 | 2008 | 252 | 0.260 |
Why?
|
Young Adult | 33 | 2024 | 59980 | 0.260 |
Why?
|
Opportunistic Infections | 1 | 2008 | 375 | 0.250 |
Why?
|
Medulloblastoma | 2 | 2022 | 682 | 0.250 |
Why?
|
Hemoglobins | 1 | 2011 | 1531 | 0.250 |
Why?
|
Alkaline Phosphatase | 2 | 2005 | 861 | 0.250 |
Why?
|
Kidney Neoplasms | 1 | 2022 | 4282 | 0.250 |
Why?
|
Siblings | 5 | 2018 | 828 | 0.240 |
Why?
|
Lung | 3 | 2019 | 10076 | 0.240 |
Why?
|
Cancer Care Facilities | 2 | 2018 | 427 | 0.240 |
Why?
|
Phytoestrogens | 1 | 2005 | 59 | 0.240 |
Why?
|
Respiratory Tract Infections | 1 | 2012 | 1009 | 0.240 |
Why?
|
Interleukin-2 | 2 | 2023 | 1894 | 0.240 |
Why?
|
Survival Analysis | 12 | 2023 | 10092 | 0.230 |
Why?
|
Bacteremia | 3 | 2019 | 983 | 0.230 |
Why?
|
Helicobacter Infections | 1 | 2008 | 390 | 0.230 |
Why?
|
Isoflavones | 1 | 2005 | 139 | 0.230 |
Why?
|
Sunlight | 2 | 2019 | 337 | 0.220 |
Why?
|
Cholinesterase Inhibitors | 1 | 2005 | 242 | 0.220 |
Why?
|
Length of Stay | 2 | 2015 | 6489 | 0.220 |
Why?
|
Poverty | 3 | 2022 | 2719 | 0.220 |
Why?
|
Lymphocyte Transfusion | 1 | 2024 | 232 | 0.210 |
Why?
|
Adrenal Cortex Hormones | 1 | 2012 | 1883 | 0.210 |
Why?
|
Lactones | 1 | 2005 | 315 | 0.210 |
Why?
|
Anticholesteremic Agents | 1 | 2010 | 969 | 0.210 |
Why?
|
Brain Neoplasms | 4 | 2020 | 9108 | 0.200 |
Why?
|
Organ Transplantation | 1 | 2012 | 1173 | 0.200 |
Why?
|
Primary Myelofibrosis | 1 | 2024 | 208 | 0.200 |
Why?
|
Busulfan | 3 | 2022 | 259 | 0.200 |
Why?
|
Survival Rate | 11 | 2024 | 12823 | 0.190 |
Why?
|
Lighting | 1 | 2023 | 210 | 0.190 |
Why?
|
Anemia, Aplastic | 3 | 2020 | 231 | 0.190 |
Why?
|
Methotrexate | 2 | 2018 | 1718 | 0.190 |
Why?
|
Guanine Nucleotide Exchange Factors | 2 | 2016 | 572 | 0.190 |
Why?
|
Anemia, Sickle Cell | 2 | 2020 | 1065 | 0.180 |
Why?
|
Hematology | 1 | 2024 | 243 | 0.180 |
Why?
|
beta-Thalassemia | 2 | 2013 | 234 | 0.180 |
Why?
|
Vitamin D Deficiency | 1 | 2010 | 1389 | 0.180 |
Why?
|
Transplants | 1 | 2023 | 208 | 0.180 |
Why?
|
Adult | 45 | 2024 | 223317 | 0.180 |
Why?
|
Patient Readmission | 1 | 2015 | 3283 | 0.180 |
Why?
|
Thiotepa | 1 | 2020 | 66 | 0.170 |
Why?
|
gamma-Globins | 1 | 2020 | 105 | 0.170 |
Why?
|
Skin Diseases | 3 | 2019 | 1083 | 0.170 |
Why?
|
Blood Donors | 2 | 2019 | 343 | 0.170 |
Why?
|
GATA2 Transcription Factor | 1 | 2020 | 158 | 0.160 |
Why?
|
Fungemia | 1 | 2019 | 57 | 0.160 |
Why?
|
Developing Countries | 3 | 2017 | 2911 | 0.160 |
Why?
|
Age Factors | 7 | 2021 | 18401 | 0.160 |
Why?
|
Incidence | 8 | 2021 | 21526 | 0.160 |
Why?
|
Leukemia, Megakaryoblastic, Acute | 1 | 2018 | 49 | 0.160 |
Why?
|
Endometrial Neoplasms | 2 | 2005 | 1381 | 0.160 |
Why?
|
Medical Oncology | 2 | 2024 | 2341 | 0.160 |
Why?
|
Estrogens | 1 | 2005 | 1536 | 0.150 |
Why?
|
Cell Division | 2 | 2005 | 4473 | 0.150 |
Why?
|
Bacillus | 1 | 2018 | 77 | 0.150 |
Why?
|
Sunburn | 1 | 2019 | 156 | 0.150 |
Why?
|
Cytogenetics | 1 | 2018 | 198 | 0.150 |
Why?
|
Chronic Disease | 9 | 2023 | 9362 | 0.150 |
Why?
|
Mouth Mucosa | 3 | 2012 | 435 | 0.150 |
Why?
|
Fetal Hemoglobin | 1 | 2020 | 346 | 0.150 |
Why?
|
Hospitals, District | 1 | 2018 | 114 | 0.150 |
Why?
|
Rhabdoid Tumor | 1 | 2020 | 211 | 0.150 |
Why?
|
Macrophage Activation Syndrome | 1 | 2019 | 124 | 0.150 |
Why?
|
Sleep | 2 | 2023 | 4816 | 0.140 |
Why?
|
Melphalan | 2 | 2017 | 421 | 0.140 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39317 | 0.140 |
Why?
|
Stomach Neoplasms | 1 | 2008 | 1481 | 0.140 |
Why?
|
Risk Factors | 17 | 2022 | 74886 | 0.140 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 1997 | 38 | 0.140 |
Why?
|
Anemia, Hemolytic | 1 | 2018 | 164 | 0.140 |
Why?
|
Preoperative Care | 2 | 2017 | 2252 | 0.140 |
Why?
|
Heart Atria | 1 | 2023 | 1362 | 0.140 |
Why?
|
Radioactive Hazard Release | 1 | 1996 | 13 | 0.140 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2024 | 1372 | 0.140 |
Why?
|
Tacrolimus | 2 | 2018 | 751 | 0.140 |
Why?
|
Teratoma | 1 | 2020 | 405 | 0.140 |
Why?
|
Cerebellar Neoplasms | 1 | 2022 | 590 | 0.140 |
Why?
|
Vitamin D | 1 | 2010 | 3312 | 0.140 |
Why?
|
Biopsy | 3 | 2019 | 6777 | 0.130 |
Why?
|
Mycophenolic Acid | 1 | 2018 | 348 | 0.130 |
Why?
|
Asparaginase | 1 | 2017 | 240 | 0.130 |
Why?
|
Antiviral Agents | 3 | 2016 | 3070 | 0.130 |
Why?
|
Germ Cells | 1 | 2020 | 644 | 0.130 |
Why?
|
Cryopreservation | 1 | 2021 | 727 | 0.130 |
Why?
|
Power Plants | 1 | 1996 | 125 | 0.130 |
Why?
|
Micronucleus Tests | 2 | 2005 | 23 | 0.130 |
Why?
|
Sepsis | 2 | 2022 | 2605 | 0.130 |
Why?
|
Immunotherapy | 5 | 2024 | 4745 | 0.130 |
Why?
|
Fellowships and Scholarships | 1 | 2024 | 1135 | 0.130 |
Why?
|
Infant, Newborn | 17 | 2020 | 26396 | 0.120 |
Why?
|
Premedication | 1 | 2016 | 245 | 0.120 |
Why?
|
Palliative Care | 3 | 2017 | 3641 | 0.120 |
Why?
|
Inpatients | 2 | 2023 | 2563 | 0.120 |
Why?
|
Vincristine | 1 | 2017 | 1040 | 0.120 |
Why?
|
Gammaretrovirus | 1 | 2014 | 24 | 0.120 |
Why?
|
Down Syndrome | 2 | 2014 | 916 | 0.120 |
Why?
|
Enzyme Induction | 2 | 2005 | 455 | 0.120 |
Why?
|
X-Linked Combined Immunodeficiency Diseases | 1 | 2014 | 24 | 0.120 |
Why?
|
Nevus, Pigmented | 1 | 2017 | 222 | 0.120 |
Why?
|
Neutropenia | 2 | 2018 | 892 | 0.120 |
Why?
|
Terminal Care | 2 | 2017 | 1770 | 0.120 |
Why?
|
Central Nervous System Diseases | 1 | 2019 | 518 | 0.120 |
Why?
|
Remission Induction | 5 | 2024 | 2408 | 0.120 |
Why?
|
Germ-Line Mutation | 2 | 2020 | 1885 | 0.120 |
Why?
|
Estrogen Receptor beta | 2 | 2005 | 171 | 0.120 |
Why?
|
Protein Kinase Inhibitors | 2 | 2024 | 5693 | 0.110 |
Why?
|
Fanconi Anemia | 1 | 2017 | 327 | 0.110 |
Why?
|
Osteochondritis Dissecans | 1 | 1996 | 119 | 0.110 |
Why?
|
Creatinine | 1 | 2020 | 1916 | 0.110 |
Why?
|
Uterine Hemorrhage | 1 | 2015 | 236 | 0.110 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2014 | 96 | 0.110 |
Why?
|
Patella | 1 | 1996 | 317 | 0.110 |
Why?
|
Combined Modality Therapy | 8 | 2024 | 8535 | 0.110 |
Why?
|
Leukemia, Myeloid | 1 | 2017 | 693 | 0.110 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 616 | 0.110 |
Why?
|
Hemoglobin M | 1 | 2013 | 3 | 0.110 |
Why?
|
Cisplatin | 1 | 2020 | 1656 | 0.110 |
Why?
|
Maximum Tolerated Dose | 2 | 2019 | 896 | 0.110 |
Why?
|
Salivary Glands | 2 | 2012 | 231 | 0.100 |
Why?
|
Viremia | 1 | 2016 | 726 | 0.100 |
Why?
|
Communication | 3 | 2024 | 3904 | 0.100 |
Why?
|
Prednisone | 1 | 2017 | 1566 | 0.100 |
Why?
|
Fatal Outcome | 4 | 2013 | 1836 | 0.100 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2017 | 2764 | 0.100 |
Why?
|
Paramyxoviridae Infections | 1 | 2012 | 57 | 0.100 |
Why?
|
Candidiasis, Oral | 1 | 2012 | 57 | 0.100 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1996 | 542 | 0.100 |
Why?
|
Delivery of Health Care | 4 | 2022 | 5363 | 0.100 |
Why?
|
Nails | 1 | 2014 | 298 | 0.100 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2022 | 1481 | 0.100 |
Why?
|
Adenovirus Infections, Human | 1 | 2012 | 76 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10748 | 0.100 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2016 | 549 | 0.100 |
Why?
|
RNA Interference | 1 | 2020 | 2829 | 0.100 |
Why?
|
Deferoxamine | 1 | 2012 | 155 | 0.100 |
Why?
|
Amenorrhea | 1 | 2015 | 484 | 0.100 |
Why?
|
Critical Illness | 3 | 2022 | 2753 | 0.100 |
Why?
|
Endocrine System Diseases | 1 | 2014 | 250 | 0.090 |
Why?
|
Codon | 1 | 2013 | 599 | 0.090 |
Why?
|
Standard of Care | 1 | 2016 | 569 | 0.090 |
Why?
|
Aneuploidy | 1 | 2015 | 573 | 0.090 |
Why?
|
Frameshift Mutation | 1 | 2013 | 392 | 0.090 |
Why?
|
Carcinoma, Papillary | 1 | 1996 | 791 | 0.090 |
Why?
|
Pandemics | 2 | 2022 | 8736 | 0.090 |
Why?
|
Estrogen Receptor alpha | 2 | 2005 | 581 | 0.090 |
Why?
|
Translocation, Genetic | 1 | 1996 | 1391 | 0.090 |
Why?
|
Adenocarcinoma | 2 | 2005 | 6360 | 0.090 |
Why?
|
Testicular Neoplasms | 1 | 1997 | 806 | 0.090 |
Why?
|
Adaptation, Psychological | 1 | 2021 | 2662 | 0.090 |
Why?
|
Genes, Dominant | 1 | 2013 | 855 | 0.090 |
Why?
|
Edema | 1 | 2014 | 764 | 0.090 |
Why?
|
Renal Dialysis | 1 | 2020 | 1790 | 0.090 |
Why?
|
Pilot Projects | 4 | 2022 | 8732 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10393 | 0.090 |
Why?
|
Time Factors | 7 | 2019 | 40154 | 0.090 |
Why?
|
Patient Selection | 2 | 2020 | 4256 | 0.090 |
Why?
|
Pentostatin | 1 | 2009 | 26 | 0.090 |
Why?
|
Semen Analysis | 1 | 2012 | 235 | 0.090 |
Why?
|
Dexamethasone | 1 | 2017 | 1963 | 0.080 |
Why?
|
Pain | 2 | 2021 | 5101 | 0.080 |
Why?
|
Survivors | 4 | 2023 | 2381 | 0.080 |
Why?
|
Eosinophilia | 1 | 2014 | 554 | 0.080 |
Why?
|
Thyroid Gland | 1 | 1996 | 1170 | 0.080 |
Why?
|
Cardiotonic Agents | 1 | 2013 | 540 | 0.080 |
Why?
|
Mouth | 1 | 2012 | 383 | 0.080 |
Why?
|
Repressor Proteins | 1 | 2020 | 2979 | 0.080 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2015 | 1149 | 0.080 |
Why?
|
Genetic Vectors | 2 | 2020 | 3402 | 0.080 |
Why?
|
Skin Neoplasms | 3 | 2019 | 5859 | 0.080 |
Why?
|
Vasoconstrictor Agents | 1 | 2013 | 655 | 0.080 |
Why?
|
Quality Improvement | 2 | 2022 | 3854 | 0.080 |
Why?
|
Acute Disease | 5 | 2023 | 7236 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1061 | 0.080 |
Why?
|
Growth Disorders | 1 | 2014 | 635 | 0.080 |
Why?
|
Adoption | 1 | 2009 | 97 | 0.080 |
Why?
|
Immunotherapy, Adoptive | 1 | 2019 | 1502 | 0.080 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4855 | 0.080 |
Why?
|
Vasodilator Agents | 1 | 2013 | 988 | 0.080 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2726 | 0.080 |
Why?
|
Dental Caries | 1 | 2012 | 429 | 0.080 |
Why?
|
Nervous System Diseases | 1 | 2019 | 1660 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 2028 | 0.080 |
Why?
|
Rural Population | 2 | 2016 | 2321 | 0.080 |
Why?
|
Blood Platelets | 1 | 2019 | 2464 | 0.070 |
Why?
|
Prognosis | 9 | 2024 | 29963 | 0.070 |
Why?
|
Creatine Kinase | 1 | 2010 | 683 | 0.070 |
Why?
|
Stomach Ulcer | 1 | 2008 | 118 | 0.070 |
Why?
|
Lip Diseases | 1 | 2007 | 18 | 0.070 |
Why?
|
Acyclovir | 1 | 2008 | 267 | 0.070 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2012 | 366 | 0.070 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2013 | 581 | 0.070 |
Why?
|
Terminally Ill | 1 | 2010 | 240 | 0.070 |
Why?
|
Health Behavior | 1 | 2019 | 2650 | 0.070 |
Why?
|
Whole-Body Irradiation | 2 | 2022 | 435 | 0.070 |
Why?
|
Egypt | 2 | 2018 | 100 | 0.070 |
Why?
|
Quality of Life | 4 | 2024 | 13485 | 0.070 |
Why?
|
Exons | 1 | 2013 | 2391 | 0.070 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2015 | 951 | 0.070 |
Why?
|
Alanine Transaminase | 1 | 2010 | 609 | 0.070 |
Why?
|
Tongue Diseases | 1 | 2007 | 69 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 2 | 2024 | 3232 | 0.070 |
Why?
|
Echocardiography, Doppler | 1 | 2011 | 898 | 0.070 |
Why?
|
Virus Activation | 1 | 2008 | 322 | 0.070 |
Why?
|
Myelitis, Transverse | 1 | 2006 | 40 | 0.070 |
Why?
|
Practice Guidelines as Topic | 4 | 2020 | 7435 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9410 | 0.060 |
Why?
|
Polyps | 1 | 2007 | 200 | 0.060 |
Why?
|
Transaminases | 1 | 2006 | 198 | 0.060 |
Why?
|
Dopamine | 1 | 2013 | 1581 | 0.060 |
Why?
|
Blood Transfusion | 1 | 2012 | 1308 | 0.060 |
Why?
|
Alternaria | 1 | 2005 | 41 | 0.060 |
Why?
|
Tissue Donors | 2 | 2020 | 2387 | 0.060 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2006 | 137 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2020 | 22254 | 0.060 |
Why?
|
Micronuclei, Chromosome-Defective | 1 | 2005 | 37 | 0.060 |
Why?
|
Antilymphocyte Serum | 2 | 2017 | 490 | 0.060 |
Why?
|
Vital Capacity | 1 | 2008 | 996 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2531 | 0.060 |
Why?
|
Cohort Studies | 9 | 2018 | 41718 | 0.060 |
Why?
|
Helicobacter pylori | 1 | 2008 | 380 | 0.060 |
Why?
|
B-Lymphocytes | 2 | 2016 | 4787 | 0.060 |
Why?
|
Food Contamination | 1 | 2005 | 193 | 0.060 |
Why?
|
Bilirubin | 2 | 2019 | 440 | 0.060 |
Why?
|
Dyskeratosis Congenita | 1 | 2004 | 70 | 0.060 |
Why?
|
Aged | 15 | 2024 | 171319 | 0.060 |
Why?
|
Parathyroid Hormone | 1 | 2010 | 1804 | 0.060 |
Why?
|
Ethics, Medical | 1 | 2009 | 785 | 0.060 |
Why?
|
Cricetulus | 1 | 2005 | 810 | 0.050 |
Why?
|
Blood Transfusion, Intrauterine | 1 | 2003 | 28 | 0.050 |
Why?
|
Sex Factors | 1 | 2017 | 10622 | 0.050 |
Why?
|
Epilepsy | 1 | 2019 | 3317 | 0.050 |
Why?
|
alpha-Thalassemia | 1 | 2003 | 53 | 0.050 |
Why?
|
Gene Expression | 4 | 2014 | 7587 | 0.050 |
Why?
|
Mouth Diseases | 1 | 2005 | 239 | 0.050 |
Why?
|
Thyroid Neoplasms | 1 | 1996 | 2355 | 0.050 |
Why?
|
Bone Marrow Examination | 1 | 2003 | 154 | 0.050 |
Why?
|
Respiratory Function Tests | 1 | 2008 | 1695 | 0.050 |
Why?
|
Calcitonin | 1 | 2004 | 328 | 0.050 |
Why?
|
General Surgery | 1 | 2014 | 1720 | 0.050 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2004 | 249 | 0.050 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2005 | 235 | 0.050 |
Why?
|
Health Policy | 1 | 2015 | 2698 | 0.050 |
Why?
|
Forced Expiratory Volume | 1 | 2008 | 1830 | 0.050 |
Why?
|
Defensins | 1 | 2002 | 35 | 0.050 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2003 | 167 | 0.050 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2005 | 719 | 0.050 |
Why?
|
Health Care Costs | 1 | 2016 | 3239 | 0.050 |
Why?
|
Postoperative Complications | 4 | 2013 | 15824 | 0.050 |
Why?
|
Acute-Phase Proteins | 1 | 2003 | 251 | 0.050 |
Why?
|
Severity of Illness Index | 5 | 2021 | 15925 | 0.050 |
Why?
|
Lymphoma | 1 | 2011 | 1896 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3112 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6513 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3234 | 0.050 |
Why?
|
Endotoxemia | 1 | 2003 | 198 | 0.050 |
Why?
|
Regression Analysis | 1 | 2011 | 6331 | 0.050 |
Why?
|
C-Reactive Protein | 2 | 2004 | 3851 | 0.050 |
Why?
|
Prospective Studies | 6 | 2023 | 54886 | 0.050 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2024 | 430 | 0.050 |
Why?
|
Decontamination | 1 | 2022 | 73 | 0.050 |
Why?
|
Flow Cytometry | 3 | 2014 | 5891 | 0.050 |
Why?
|
Cricetinae | 1 | 2005 | 2415 | 0.050 |
Why?
|
Lymphoproliferative Disorders | 1 | 2005 | 527 | 0.050 |
Why?
|
Middle Aged | 15 | 2024 | 223233 | 0.050 |
Why?
|
Disease Progression | 1 | 2019 | 13646 | 0.050 |
Why?
|
Lymphatic Diseases | 1 | 2003 | 318 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2014 | 3618 | 0.050 |
Why?
|
Influenza, Human | 1 | 2012 | 1543 | 0.050 |
Why?
|
Anthracyclines | 1 | 2023 | 286 | 0.050 |
Why?
|
Logistic Models | 2 | 2013 | 13284 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6550 | 0.050 |
Why?
|
Brain Diseases | 1 | 2010 | 1551 | 0.040 |
Why?
|
Hospitalization | 3 | 2023 | 10815 | 0.040 |
Why?
|
Heart Diseases | 1 | 2013 | 2817 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2005 | 12793 | 0.040 |
Why?
|
Diagnosis, Differential | 4 | 2019 | 12986 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2014 | 4648 | 0.040 |
Why?
|
Hospitals | 2 | 2023 | 3883 | 0.040 |
Why?
|
Cholagogues and Choleretics | 1 | 2019 | 39 | 0.040 |
Why?
|
Protein Precursors | 1 | 2004 | 1134 | 0.040 |
Why?
|
Body Mass Index | 1 | 2018 | 13048 | 0.040 |
Why?
|
Ursodeoxycholic Acid | 1 | 2019 | 81 | 0.040 |
Why?
|
Pruritus | 1 | 2003 | 378 | 0.040 |
Why?
|
Models, Biological | 1 | 2016 | 9464 | 0.040 |
Why?
|
Radiotherapy | 1 | 2006 | 1500 | 0.040 |
Why?
|
Bleomycin | 1 | 2020 | 492 | 0.040 |
Why?
|
Back Pain | 1 | 2003 | 547 | 0.040 |
Why?
|
Chromosome Aberrations | 1 | 2005 | 1776 | 0.040 |
Why?
|
Vinblastine | 1 | 2020 | 482 | 0.040 |
Why?
|
Complement Inactivating Agents | 1 | 2019 | 53 | 0.040 |
Why?
|
Cross-Sectional Studies | 5 | 2019 | 26325 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3207 | 0.040 |
Why?
|
Liver | 2 | 2012 | 7578 | 0.040 |
Why?
|
Thoracic Vertebrae | 1 | 2003 | 613 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 232 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2005 | 17097 | 0.040 |
Why?
|
Vancomycin | 1 | 2021 | 504 | 0.040 |
Why?
|
Homozygote | 1 | 2003 | 1774 | 0.040 |
Why?
|
Erythrocyte Count | 1 | 2018 | 157 | 0.040 |
Why?
|
Hearing Disorders | 1 | 1998 | 126 | 0.040 |
Why?
|
Ritonavir | 1 | 2020 | 331 | 0.040 |
Why?
|
Leg | 1 | 2003 | 1087 | 0.040 |
Why?
|
Postoperative Period | 2 | 2019 | 1824 | 0.040 |
Why?
|
Ecosystem | 1 | 2022 | 489 | 0.040 |
Why?
|
United States | 6 | 2024 | 72971 | 0.040 |
Why?
|
Podophyllotoxin | 1 | 2017 | 20 | 0.040 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 1999 | 168 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2020 | 619 | 0.040 |
Why?
|
Nail Diseases | 1 | 2018 | 54 | 0.040 |
Why?
|
Carmustine | 1 | 2017 | 137 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2010 | 3446 | 0.040 |
Why?
|
Ultrasonography, Doppler | 1 | 2019 | 463 | 0.040 |
Why?
|
Dacarbazine | 1 | 2020 | 552 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 613 | 0.040 |
Why?
|
Focus Groups | 1 | 2023 | 1460 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 638 | 0.040 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 1 | 2016 | 7 | 0.030 |
Why?
|
Vitiligo | 1 | 2018 | 97 | 0.030 |
Why?
|
Cell Cycle | 1 | 2005 | 2927 | 0.030 |
Why?
|
Pediatrics | 2 | 2024 | 3621 | 0.030 |
Why?
|
Respiration Disorders | 1 | 2020 | 364 | 0.030 |
Why?
|
Stroke Volume | 1 | 2011 | 5618 | 0.030 |
Why?
|
Blood Proteins | 1 | 2002 | 1190 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2022 | 1012 | 0.030 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3700 | 0.030 |
Why?
|
Education, Distance | 1 | 2020 | 260 | 0.030 |
Why?
|
Blast Crisis | 1 | 2016 | 102 | 0.030 |
Why?
|
Ukraine | 1 | 1996 | 151 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1604 | 0.030 |
Why?
|
Platelet Count | 1 | 2019 | 784 | 0.030 |
Why?
|
Comorbidity | 1 | 2011 | 10582 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 427 | 0.030 |
Why?
|
Parents | 1 | 2010 | 3594 | 0.030 |
Why?
|
Joint Deformities, Acquired | 1 | 1996 | 35 | 0.030 |
Why?
|
Leg Length Inequality | 1 | 1996 | 56 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 878 | 0.030 |
Why?
|
Vidarabine | 1 | 2017 | 337 | 0.030 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 1996 | 377 | 0.030 |
Why?
|
Cytarabine | 1 | 2017 | 695 | 0.030 |
Why?
|
Goserelin | 1 | 2015 | 126 | 0.030 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1996 | 432 | 0.030 |
Why?
|
Esophageal Neoplasms | 1 | 2005 | 1661 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2003 | 928 | 0.030 |
Why?
|
Lymphocyte Depletion | 1 | 2017 | 605 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 1733 | 0.030 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2014 | 89 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2020 | 1079 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2002 | 2412 | 0.030 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 1996 | 640 | 0.030 |
Why?
|
Contraceptive Agents, Female | 1 | 2015 | 123 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2920 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2004 | 3227 | 0.030 |
Why?
|
T-Lymphocytes | 3 | 2017 | 10254 | 0.030 |
Why?
|
Quality Assurance, Health Care | 1 | 2024 | 2174 | 0.030 |
Why?
|
Leuprolide | 1 | 2015 | 313 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 2086 | 0.030 |
Why?
|
Resuscitation Orders | 1 | 2016 | 271 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3344 | 0.030 |
Why?
|
Alopecia | 1 | 2018 | 416 | 0.030 |
Why?
|
Nitriles | 1 | 2019 | 980 | 0.030 |
Why?
|
Doxorubicin | 1 | 2020 | 2229 | 0.030 |
Why?
|
Prevalence | 1 | 2010 | 15851 | 0.030 |
Why?
|
Down-Regulation | 1 | 2020 | 2931 | 0.030 |
Why?
|
Iodine Radioisotopes | 1 | 1996 | 1029 | 0.030 |
Why?
|
Membrane Glycoproteins | 1 | 2003 | 3702 | 0.030 |
Why?
|
Histocompatibility Testing | 2 | 2004 | 717 | 0.030 |
Why?
|
Infection Control | 1 | 2020 | 984 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2824 | 0.030 |
Why?
|
Bone Marrow Diseases | 1 | 2014 | 234 | 0.030 |
Why?
|
Cytokines | 2 | 2019 | 7446 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2008 | 20741 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2014 | 655 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2024 | 2420 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2003 | 2906 | 0.020 |
Why?
|
Consanguinity | 1 | 2014 | 460 | 0.020 |
Why?
|
Brain | 1 | 2019 | 27163 | 0.020 |
Why?
|
Models, Organizational | 1 | 2015 | 548 | 0.020 |
Why?
|
Information Dissemination | 1 | 2020 | 1142 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2021 | 1592 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 2014 | 899 | 0.020 |
Why?
|
Policy Making | 1 | 2015 | 546 | 0.020 |
Why?
|
Growth Hormone | 1 | 2014 | 572 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 3427 | 0.020 |
Why?
|
New England | 1 | 2014 | 1058 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2302 | 0.020 |
Why?
|
DNA, Complementary | 1 | 2014 | 1989 | 0.020 |
Why?
|
Cyclosporine | 1 | 2014 | 778 | 0.020 |
Why?
|
Transgenes | 1 | 2014 | 1014 | 0.020 |
Why?
|
Hypotension | 1 | 2017 | 888 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12069 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 1996 | 2509 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2003 | 4925 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2019 | 2209 | 0.020 |
Why?
|
Cause of Death | 1 | 2021 | 3717 | 0.020 |
Why?
|
Psoriasis | 1 | 2018 | 925 | 0.020 |
Why?
|
Neutrophils | 1 | 2002 | 3779 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2021 | 1945 | 0.020 |
Why?
|
Decision Making | 2 | 2016 | 3951 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5311 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2337 | 0.020 |
Why?
|
Living Donors | 1 | 2014 | 647 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2016 | 1854 | 0.020 |
Why?
|
Program Development | 1 | 2015 | 1298 | 0.020 |
Why?
|
Range of Motion, Articular | 1 | 1996 | 1597 | 0.020 |
Why?
|
Registries | 2 | 2016 | 8351 | 0.020 |
Why?
|
Hypothyroidism | 1 | 2014 | 667 | 0.020 |
Why?
|
Statistics, Nonparametric | 2 | 2004 | 2850 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1512 | 0.020 |
Why?
|
Gene Silencing | 1 | 2014 | 1505 | 0.020 |
Why?
|
Hemorrhage | 1 | 2020 | 3464 | 0.020 |
Why?
|
Immunoglobulin E | 1 | 2014 | 1496 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9660 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 1405 | 0.020 |
Why?
|
Medicaid | 1 | 2021 | 2836 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2014 | 1271 | 0.020 |
Why?
|
Attitude to Death | 1 | 2010 | 400 | 0.020 |
Why?
|
Program Evaluation | 1 | 2015 | 2505 | 0.020 |
Why?
|
Pyrimidines | 1 | 2019 | 3044 | 0.020 |
Why?
|
Pedigree | 1 | 2014 | 4539 | 0.020 |
Why?
|
Animals | 4 | 2022 | 168965 | 0.020 |
Why?
|
Income | 1 | 2014 | 1877 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2019 | 3114 | 0.020 |
Why?
|
Critical Care | 1 | 2018 | 2714 | 0.020 |
Why?
|
Brain Edema | 1 | 2010 | 601 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2002 | 7868 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 8068 | 0.020 |
Why?
|
Leukoplakia | 1 | 2004 | 18 | 0.020 |
Why?
|
Liver Function Tests | 1 | 2006 | 526 | 0.010 |
Why?
|
Radiography | 1 | 1996 | 6975 | 0.010 |
Why?
|
Inflammation | 2 | 2019 | 10869 | 0.010 |
Why?
|
Monitoring, Immunologic | 1 | 2004 | 99 | 0.010 |
Why?
|
Hyperplasia | 1 | 2007 | 1150 | 0.010 |
Why?
|
Leukoplakia, Oral | 1 | 2004 | 79 | 0.010 |
Why?
|
Surgical Procedures, Operative | 1 | 1996 | 1931 | 0.010 |
Why?
|
Patient Care Team | 1 | 2015 | 2516 | 0.010 |
Why?
|
Laos | 1 | 2003 | 27 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10455 | 0.010 |
Why?
|
Mice | 3 | 2022 | 81912 | 0.010 |
Why?
|
Skinfold Thickness | 1 | 2003 | 164 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7469 | 0.010 |
Why?
|
Risk | 1 | 2015 | 9606 | 0.010 |
Why?
|
Tongue Neoplasms | 1 | 2004 | 186 | 0.010 |
Why?
|
Boston | 1 | 2015 | 9360 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 1999 | 9245 | 0.010 |
Why?
|
Liver Diseases | 1 | 2011 | 1304 | 0.010 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2004 | 238 | 0.010 |
Why?
|
Transcription Factors | 1 | 2022 | 12158 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7848 | 0.010 |
Why?
|
Cell Extracts | 1 | 2002 | 134 | 0.010 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2004 | 340 | 0.010 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2004 | 327 | 0.010 |
Why?
|
Cells, Cultured | 1 | 1996 | 18989 | 0.010 |
Why?
|
Postnatal Care | 1 | 2003 | 273 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11217 | 0.010 |
Why?
|
Myocardium | 1 | 2013 | 4765 | 0.010 |
Why?
|
Arm | 1 | 2003 | 591 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 1999 | 18330 | 0.010 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2002 | 350 | 0.010 |
Why?
|
Graft Survival | 2 | 2004 | 3896 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2014 | 3986 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2015 | 3414 | 0.010 |
Why?
|
Mesentery | 1 | 1980 | 201 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2005 | 1396 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2476 | 0.010 |
Why?
|
Anthropometry | 1 | 2003 | 1345 | 0.010 |
Why?
|
Muscles | 1 | 2003 | 1576 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2016 | 4881 | 0.010 |
Why?
|
Rest | 1 | 2003 | 941 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 14098 | 0.010 |
Why?
|
Lung Transplantation | 1 | 2007 | 1310 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2004 | 3431 | 0.010 |
Why?
|
Risk Assessment | 2 | 2012 | 24299 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2022 | 59548 | 0.010 |
Why?
|
Intestinal Obstruction | 1 | 1980 | 433 | 0.010 |
Why?
|
ROC Curve | 1 | 2004 | 3618 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1999 | 2012 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2004 | 6215 | 0.010 |
Why?
|
Escherichia coli Proteins | 1 | 2002 | 1055 | 0.010 |
Why?
|
Reference Values | 1 | 2002 | 4918 | 0.010 |
Why?
|
Immunophenotyping | 1 | 1999 | 1864 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2010 | 4526 | 0.010 |
Why?
|
Mice, SCID | 1 | 1999 | 2626 | 0.010 |
Why?
|
Patient Compliance | 1 | 2004 | 2697 | 0.010 |
Why?
|
Intestine, Small | 1 | 1980 | 1217 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 4572 | 0.010 |
Why?
|
Physicians | 1 | 2010 | 4593 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 18063 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 1999 | 2391 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 1999 | 2428 | 0.010 |
Why?
|
Mutation | 1 | 2014 | 30211 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2004 | 14672 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 1996 | 36582 | 0.000 |
Why?
|
Predictive Value of Tests | 1 | 2004 | 15424 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1999 | 11063 | 0.000 |
Why?
|
Pregnancy | 1 | 2003 | 30238 | 0.000 |
Why?
|
Methods | 1 | 1980 | 1065 | 0.000 |
Why?
|
Peritonitis | 1 | 1980 | 368 | 0.000 |
Why?
|